ClinicalTrials.gg
CompletedNCT00048230Updated Jan 13, 2012

PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

A Phase 3 interventional study of bortezomib in Multiple Myeloma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 93 sites in 13 countries. Per ClinicalTrials.gov, last updated 2012-01-13.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
620
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 271 studies testing bortezomib in Multiple Myeloma — 12 open to participants now, 40 under way, 14 of them phase 3. Bortezomib · Multiple Myeloma.

Enrollment
6th of 267
620 · median 41
Started
2002
with 1 other
Phase 3
42 of 271
1 open now
Registered
3rd of 271
by date
Lead sponsor
6 of 271
Millennium Pharmaceuticals, Inc.

Among the 271 studies testing bortezomib in Multiple Myeloma, this one is the 6th largest by enrollment of the 267 interventional ones that give a count, is one of 2 that started in 2002, is one of 42 in phase 3, and was the 3rd registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

12 of the 271 studies testing bortezomib in Multiple Myeloma are open now, in 10 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About bortezomib

Bortezomib: first FDA approval 2003 (VELCADE), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 584 Multiple Myeloma studies recruiting now, 429 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 271 studies testing bortezomib in Multiple Myeloma, or all of them as a file.
02

Study summary

This study will compare the efficacy of PS-341 versus high dose dexamethasone.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Relapsed Multiple Myeloma
  • Refractory Multiple Myeloma
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is of a legally consenting age, as defined by local regulations.
  • Patient is, in the investigator's opinion, willing and able to comply with the protocol requirements.
  • Patient has given voluntary written before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care.
  • Female patient is either or surgically sterilized or willing to use an acceptable method of (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study.
  • Male patient agrees to use an acceptable method for contraception for the duration of the study.
  • Patient was previously diagnosed with multiple myeloma based on standard criteria and currently requires second-, third-, or fourth-line therapy because of PD, defined as a 25% increase in M-protein, development of new or worsening of existing lytic bone lesions or soft tissue plasmacytomas, or hypercalcemia (serum calcium >11.5 mg/dL), or relapse from CR.
  • Patient has , defined as follows:
  • For secretory multiple myeloma, measurable disease is defined as any quantifiable serum monoclonal protein value (generally, but not exclusively, greater than 1 g/dL of IgG M-Protein and greater than 0.5g/dL IgA) and, where applicable, urine light-chain excretion of ≥200 mg/24 hours.
  • For oligo- or non-secretory multiple myeloma, measurable disease is defined by the presence of soft tissue (not bone) plasmacytomas as determined by clinical examination or applicable radiographs (i.e. MRI, CT-Scan). In patients with oligosecretory multiple myeloma, the serum and/or urine M-protein measurements are very low and difficult to follow for response assessments. Therefore, other disease sites (bone marrow; extramedullary mass) must be assessed and followed. In patients with non-secretory multiple myeloma, there is no M-protein in serum or urine by immunofixation.
  • Patient has a performance status ≥60%.
  • Patient has a life-expectancy >3 months.
  • Patient has the following laboratory values at and within 14 days before Baseline (Day 1 of Cycle 1, before study drug administration):
  • count ≥50 x 10E+9/L without transfusion support within 7 days before the laboratory test.
  • ≥7.5 g/dL, without transfusion support within 7 days before the laboratory test.
  • (ANC) ≥0.75 x 10E+9/L without the use of colony stimulating factors.
  • Corrected serum calcium \<14 mg/dL (3.5 mmol/L).
  • (AST): ≤2.5 x the (ULN).
  • Alanine transaminase (ALT): ≤2.5 x the ULN.
  • Total : ≤1.5 x the ULN.
  • Calculated or measured : ≥20 mL/minute.

Exclusion criteria

Exclusion Criteria

  • Patient previously received treatment with VELCADE.
  • Patient previously was to treatment with high-dose dexamethasone, as experiencing less than a partial response to or PD within 6 months after discontinuing dexamethasone, or discontinued dexamethasone because of ≥Grade 3 dexamethasone-related toxicity.
  • Previous high-dose dexamethasone therapy is defined as >500 mg dexamethasone or equivalent over a 10-week period, whether administered alone or as part of the VAD regimen.
  • Patient received nitrosoureas within 6 weeks or any other chemotherapy, including thalidomide or clarithromycin, or radiation therapy within 3 weeks before enrollment.
  • Patient received (>10 mg/day prednisone or equivalent) within 3 weeks before enrollment.
  • Patient received immunotherapy or antibody therapy within 8 weeks before enrollment.
  • Patient received plasmapheresis within 4 weeks before enrollment.
  • Patient had major surgery within 4 weeks before enrollment. (Kyphoplasty is not considered major surgery.)
  • Patient has a history of allergic reaction attributable to compounds containing boron or mannitol.
  • Patient has peripheral neuropathy of Grade 2 or greater intensity, as defined by the NCI Common Toxicity Criteria (NCI CTC):
  • Grade 2: Objective sensory loss or paresthesia (including tingling), interfering with function, but not interfering with activities of daily living (ADLs).
  • Grade 3: Sensory loss or paresthesia interfering with ADLs.
  • Grade 4: Permanent sensory loss that interferes with function.
  • Patient had a myocardial infarction within 6 months of enrollment or has (NYHA) Class III or IV heart failure uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
  • Patient was treated for a cancer other than multiple myeloma within 5 years before enrollment, with the exception of basal cell carcinoma or cervical cancer in situ.
  • Patient has cardiac amyloidosis.
  • Patient has poorly controlled hypertension, diabetes mellitus, or other serious medical or psychiatric illness that could potentially interfere with the completion of treatment according to this protocol.
  • Patient is known to be (HIV)-positive. (Patients assessed by the investigator to be at risk for HIV infection should be tested in accordance with local regulations.)
  • Patient is known to be surface antigen-positive or has known active infection.
  • Patient has an active systemic infection requiring treatment.
  • Female patient is pregnant or breast-feeding.
  • Patient currently is enrolled in another clinical research study and/or is receiving an agent for any reason.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
620 participants (actual)

Interventions

06

Study locations

93 sites
  • Alta Bates Comprehensive Cancer Center
    Berkeley, California 94704, United States
  • City of Hope
    Duarte, California 91010, United States
  • Scripps Clinic
    La Jolla, California 92307, United States
  • Loma Linda University Medical Center
    Loma Linda, California 92354, United States
  • Kaiser Permanente Oncology Clinical Trials
    Vallejo, California 94589, United States
  • Lombardi Cancer Center, Georgetown University Medical Center
    Washington, District of Columbia 20007, United States
  • Med Star Institute, Washington Cancer Center
    Washington, District of Columbia 20010, United States
  • Hematology/Oncology Associates, PA
    Jacksonville, Florida 32207, United States
  • University of Miami
    Miami, Florida 33136, United States
  • H. Lee Moffitt Cancer Center, University of S. Florida
    Tampa, Florida 33612, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Northwestern University Medical School
    Chicago, Illinois 60611, United States
  • Loyola University Medical Center: Cardinal Bernardin Cancer Center
    Maywood,, Illinois 60153, United States
  • LSU HC
    Shreveport, Louisiana 71130, United States
  • Tufts New England Medical Center
    Boston, Massachusetts 02111, United States
  • Dana-Farber Cancer Center
    Boston, Massachusetts 02115, United States
  • Beth Israel Deaconess Medical Center, Kirstein Room 135
    Boston, Massachusetts 02215, United States
  • Department of Internal Medicine, Univ. of Michigan Comp. Cancer Center
    Ann Arbor, Michigan 48109-0922, United States
  • VA Medical Center, Sections of Hematology/Oncology
    Minneapolis, Minnesota 55417, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Washington University School of Medicine
    St. Louis, Missouri 63110, United States
  • Hackensack University Medical Center, David Jurist Research Building
    Hackensack, New Jersey 07601, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Long Island Jewish Medical Center, Division of Hematology/Oncology
    New Hyde Park, New York 11040, United States
  • St. Vincent's Comprehensive Cancer Center, Research Department
    New York, New York 10011, United States
  • NY Presbyterian Hospital
    New York, New York 10021, United States
  • Rochester General Hospital, Lipson Cancer Blood Center
    Rochester, New York 14621, United States
  • University of Rochester Medical Center, James P. Wilmot Cancer Center
    Rochester, New York 14642, United States
  • Carolinas Hematology-Oncology Associates
    Charlotte, North Carolina 28203, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • University of Pennsylvania Cancer Center
    Philadelphia, Pennsylvania 19104, United States
  • Western Pennsylvania Hospital, Dept. of Human Oncology
    Pittsburgh, Pennsylvania 15224, United States
  • Trident Palmetto Hematology/Oncology
    Charleston, South Carolina 29406, United States
  • Division of Hematology/Stem Cell Transplant
    Nashville, Tennessee 37232-5505, United States
  • Texas Oncology at Medical City Dallas Hospital
    Dallas, Texas 75225, United States
  • Baylor Institute for Immunology Research
    Dallas, Texas 75246, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Fred Hutchinson Cancer Center
    Seattle, Washington 98109, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Wilhelminenspital Wien, Abt. Fur Med. und Medizinische Onkologie
    Wien, 1171, Austria
  • ACZA, Campus Stuivenberg
    Antwerpen, 2060, Belgium
  • CHU Erasme / ULB University, Hematology 7th Floor
    Brussels, 1070, Belgium
  • Institut Jules Bordet, Unite Sterile
    Bruxelles, 1000, Belgium
  • C.H. Notre Dame-Reine Fabiola
    Charleroi, 6000, Belgium
  • UZ Gasthuisberg, Department of Hematology
    Leuven, 3000, Belgium
  • AZ St. Jan, Dept. of Haematology
    Rugge, 8000, Belgium
  • Cliniques Universitaires U.C.L de Mont Godinne, Hopital de Jour
    Yvoir, 5530, Belgium
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
  • London Health Sciences Center
    London, Ontario N6A 4G5, Canada
  • Toronto General Research Institute, Princess Margaret Hospital
    Toronto, Ontario M5G2M9, Canada
  • Royal Victoria Hospital
    Montreal, Quebec H2W 1S6, Canada
  • Hospital Claude Huriez, Service des Maladies du Sang
    Lile, Cedex 59037, France
  • Nantes Hotel Dieu Hospital
    Nantes, Cedex 01 44093, France
  • Hopital Purpan, Pavillon Dieulafoy, Service d'Hematologie Clinique
    Toulouse, Cedex 31059, France
  • Institut Gustave-Roussy, Service d'Hematologie
    Villejuif, Cedex 94805, France
  • Hopital Antoine Beclere, Hopital de Jour de Medecine Interne
    Clamart, 92140, France
  • Hopital Hotel Dieu, Service d'hematologie et oncologie medicale
    Paris, 75004, France
  • Hopital Saint-Louis, Direction Financiere
    Paris, 75010, France
  • Hopital Cochin, Service de Hematologie
    Paris, 75014, France
  • Centre Hospitalier Lyon Sud
    Pierre Benite Cedex, 69495, France
  • Hopital de Brabois, Service Hematologie et Medecine Interne
    Vandoeuvre, 54511, France
  • Universitatsklinikum Charite, Abt. Fuer Haematologie/Onkologie
    Berlin, 10098, Germany
  • Medizinische Klinik und Poliklinik 1
    Bonn, 53127, Germany
  • Universitatsklinikum Carl Gustav Carus
    Dresden, 01307, Germany
  • University of Erlangen-Nurenberg, Division of Hematology/Oncology
    Erlangen, 91054, Germany
  • Freiburg University Medical Center, Dept. of Hemayology/Oncology
    Freiburg, 79106, Germany
  • Medical University Clinic (Oncology/Haematology)
    Hamburg, 20246, Germany
  • St. Marien Hospital, Klinik fur Hamatologie und Onkologie
    Hamm, 59071, Germany
  • Universitatsklinikum Heidelberg, Abt. Fur Haematologie und Onkologie
    Heidelberg, 69115, Germany
  • University of Essen Medical School, Dept. of Internal Medicine
    Hufelandstr, 55 45122, Germany
  • Johannes Gutenberg-Universitat Mainz, III. Med Klinik und Poliknik
    Mainz, 55101, Germany
  • Uniklinikum Muenster
    Muenster, 48129, Germany
  • Eberhard-Karls Universitat, Medizinische Klinik
    Tubingen, 72076, Germany
  • Belfast City Hospital
    Belfast, BT9 7AB, Ireland
  • RAMBAM Medical Center, Department of Hematology and Bone
    Haifa, 31096, Israel
  • Hadassah University Hospital
    Jerusalem, 91120, Israel
  • Dipartmento Clinico esperimentale Di Oncologia et Ematolgia
    Bergamo, 24128, Italy
  • Instituto di Ematologia e Oncologia Medica, Lorenzo e Ariosto Seragnoli
    Bologna, 40138, Italy
  • Dipartimento di Biotecnologie Cellulari ed Ematologia
    Roma, 00161, Italy
  • Azienda Ospedaliera, S. Giovanni Battista
    Torino, 10126, Italy
  • Dept. of Clinical Hematology, Academic Medical Center
    Amsterdam, 1105, Netherlands
  • Department of Hematology, Erasmus MC, 1a, Daniel Den Hoed
    Rotterdam, 3075, Netherlands
  • Dept. Hematology, University Medical Centre
    Utrecht, 3584 CX, Netherlands
  • Hospital Clinico Universitario de Barcelona, Haematology Department
    Barcelona, 08036, Spain
  • University Hospital of Salamanca
    Salamanca, 37007, Spain
  • Department of Haematology, Huddinge University Hospital M54
    Stockholm, 14186, Sweden
  • Karolinska Hospital, Dept. of Hematology
    Stockholm, 17176, Sweden
  • Adult Leukaemia Unit, Christie Hospital
    Withington, Manchester M20 4BX, United Kingdom
  • Department of Haematology, Queen Elizabeth Hospital
    Birmingham, B15 2TH, United Kingdom
  • Leeds General Infirmary
    Leeds, LS1 3EX, United Kingdom
  • Department of Haematology, St. Bartholomew's Hospital
    London, EC1A 7BE, United Kingdom
  • Department of Haematology, ICSM, Hammersmith Hospital
    London, W12 0NN, United Kingdom
  • Royal Marsden Hospital, Leukaemia and Myeloma Units
    Sutton, SM2 5PT, United Kingdom
07

References and documents

Publications

  • Dimopoulos MA, Orlowski RZ, Facon T, Sonneveld P, Anderson KC, Beksac M, Benboubker L, Roddie H, Potamianou A, Couturier C, Feng H, Ataman O, van de Velde H, Richardson PG. Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma. Haematologica. 2015 Jan;100(1):100-6. doi: 10.3324/haematol.2014.112037. Epub 2014 Sep 26. PubMed 25261096 ↗
  • Lichter DI, Danaee H, Pickard MD, Tayber O, Sintchak M, Shi H, Richardson PG, Cavenagh J, Blade J, Facon T, Niesvizky R, Alsina M, Dalton W, Sonneveld P, Lonial S, van de Velde H, Ricci D, Esseltine DL, Trepicchio WL, Mulligan G, Anderson KC. Sequence analysis of beta-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone. Blood. 2012 Nov 29;120(23):4513-6. doi: 10.1182/blood-2012-05-426924. Epub 2012 Sep 27. PubMed 23018640 ↗
  • van Duin M, Broyl A, de Knegt Y, Goldschmidt H, Richardson PG, Hop WC, van der Holt B, Joseph-Pietras D, Mulligan G, Neuwirth R, Sahota SS, Sonneveld P. Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy. Haematologica. 2011 Nov;96(11):1662-9. doi: 10.3324/haematol.2010.037978. Epub 2011 Jul 26. PubMed 21791470 ↗
  • Vogl DT, Stadtmauer EA, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Facon T, Harousseau JL, Boral A, Neuwirth R, Anderson KC. Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma. Br J Haematol. 2009 Nov;147(4):531-4. doi: 10.1111/j.1365-2141.2009.07875.x. Epub 2009 Sep 1. PubMed 19725827 ↗
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2002, a primary completion of Jul 2004 and a completion of Dec 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2002
First posted
Oct 30, 2002
Start
Jun 2002
Primary completionActual
Jul 2004
CompletionActual
Dec 2004
Last update
Jan 13, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00048230
Responsible party
Sponsor
First posted
Oct 30, 2002
Start date
Jun 2002
Primary completion
Jul 2004
Completion
Dec 2004
Last update
Jan 13, 2012
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bortezomib

Start the discussion